Beclomethasone Side Effects

Not all side effects for beclomethasone may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to beclomethasone: inhalation aerosol liquid, inhalation aerosol powder, inhalation capsule, inhalation spray

In addition to its needed effects, some unwanted effects may be caused by beclomethasone. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking beclomethasone:

More common
  • Body aches or pain
  • congestion
  • cough
  • difficulty with breathing
  • dryness or soreness of the throat
  • fever
  • hoarseness
  • runny nose
  • tender, swollen glands in the neck
  • trouble swallowing
  • voice changes
Incidence not known
  • Attack, assault, or force
  • blindness
  • blurred vision
  • changes in behavior
  • chills
  • darkening of the skin
  • decreased vision
  • diarrhea
  • dizziness
  • eye pain
  • fainting
  • headache
  • loss of appetite
  • lower back or side pain
  • mental depression
  • nausea or vomiting
  • painful or difficult urination
  • skin rash
  • sore mouth or tongue
  • tearing
  • thoughts of killing oneself
  • unusual tiredness or weakness
  • white patches in the mouth or on the tongue

Some of the side effects that can occur with beclomethasone may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Cramps
  • heavy bleeding
  • pain
  • pain or tenderness around the eyes and cheekbones
  • stuffy or runny nose
  • tightness of the chest

For Healthcare Professionals

Applies to beclomethasone: compounding powder, inhalation aerosol, inhalation aerosol with adapter


Beclomethasone is generally well tolerated and, due to the nature of its administration, is not inclined to produce the systemic adverse effects generally associated with the use of corticosteroids.[Ref]


Gastrointestinal adverse effects due to beclomethasone are reported most commonly. Oropharyngeal candidiasis occurs in approximately 5% to 14% of patients treated with beclomethasone and occurs more often at higher dosages greater than 800 mcg per day. Candidiasis is generally limited to the oropharyngeal area.[Ref]

Although candidiasis is generally limited to the oropharyngeal area, rare cases of esophageal candidiasis have been reported. To reduce the incidence of thrush, patients should be instructed to rinse their mouths following the use of beclomethasone. Limited data suggest that the incidence of thrush may be lower in patients utilizing a spacer device and good inhalation technique.[Ref]


Respiratory side effects have commonly included dysphonia and sore throat in patients receiving beclomethasone. This may or may not occur in the presence of oral thrush. Coughing and wheezing have frequently been reported with inhaled beclomethasone use, especially in patients whose disease is under poor control.[Ref]

One study suggests that dysphonia occurring in the absence of oral thrush may be due to a vocal cord abnormality attributable to inhaled steroid use. In some cases, dysphonia and vocal cord abnormalities persisted for months following discontinuation of beclomethasone.

Many patients experiencing coughing and wheezing may benefit from pretreatment with an inhaled beta agonist prior to administration of beclomethasone.

Pulmonary eosinophilia, apparently associated with beclomethasone use, has been reported in at least two patients.[Ref]


Endocrine abnormalities associated with beclomethasone rarely include suppression of the hypothalamus-pituitary-adrenal axis. The risk of adrenal suppression is less than that associated with systemic corticosteroids and occurs less frequently with daily doses of 2 mg per day or lower. The use of a large-volume spacer may also help minimize HPA suppression when beclomethasone is inhaled orally.[Ref]


Immunologic effects of infection from immune suppression associated with inhaled corticosteroids have been debated. No conclusive evidence is available to support an increase in tuberculosis or viral infections in patients receiving inhaled beclomethasone.[Ref]

In a study of 548 asthmatic patients receiving beclomethasone, eight patients developed tuberculosis. Two patients who agreed to resume beclomethasone use following treatment experienced a reactivation of tuberculosis within 2 weeks.

In 1993, the American Academy of Allergy and Immunology (AAAI) requested that the FDA review its decision regarding the relabeling of inhaled corticosteroids following concerns about the risk of their use during severe viral infections. The AAAI's request was based on the lack of data linking inhaled corticosteroids to increases in complications of viral infections.[Ref]


Musculoskeletal side effects from long-term use of inhaled beclomethasone may be associated with a reduction in bone density. This effect may be dose-related and has been reported with high dosages (>=800 mcg/day for >= 1 year). Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.[Ref]

The reduction in bone density may be due to suppressed osteoblast function, as evidenced by decreased serum osteocalcin levels.[Ref]


Ocular adverse effects are more commonly seen with systemic administration of corticosteroids. However, posterior capsular cataracts have been occasionally reported with beclomethasone use, especially with long-term use. In addition, one epidemiologic study suggests that prolonged use of high-dose inhaled corticosteroids (>= 1600 mcg of beclomethasone) may be associated with increased risk of ocular hypertension and open angle glaucoma.[Ref]


Dermatologic adverse effects may include acne. Skin atrophy and easy bruising has been associated with beclomethasone use in some patients.[Ref]

In one prospective study, patients receiving at least 1 mg/day of inhaled beclomethasone (or 800 mcg of budesonide) for 3 months or more had a significantly higher incidence of ecchymosis than matched controls. In addition, the severity was more pronounced in the treatment group. Older patients were more likely to be affected. The presence of skin bruising was associated with lower urinary cortisol levels, suggesting systemic absorption of the inhaled drug.[Ref]


Psychiatric adverse effects include rare cases of mania.

Postmarketing reports have included cases of psychiatric events and behavioral changes (aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation) primarily in children.[Ref]

Nervous system

Nervous system side effects have included headache.[Ref]


1. Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984): 99-126

2. Brannan MD, Herron JM, Reidenberg P, Affrime MB "Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis." Clin Ther 17 (1995): 637-47

3. "Product Information. Qvar (beclomethasone)." Teva Pharmaceuticals USA, North Wales, PA.

4. Hemstreet MP, Reynolds DW, Meadows J Jr "Oesophagitis--a complication of inhaled steroid therapy." Clin Allergy 10 (1980): 733-8

5. Greening AP "Clinical issues in the treatment of adult asthma." Respir Med 91 (1997): 38-9

6. Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982): 235-42

7. Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995): 868-75

8. Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974): 797-8

9. Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980): 145-53

10. "Product Information. Vancenase (beclomethasone)." Glaxo Wellcome, Research Triangle Park, NC.

11. Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988): 568-9

12. "Product Information. Beclovent (beclomethasone)." Glaxo Wellcome, Research Triangle Park, NC.

13. McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997): 732-43

14. Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979): 205-10

15. Brown PH, Greening AP, Crompton GK "Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function." Thorax 48 (1993): 233-8

16. Williams AJ, Baghat MS, Stableforth DE, Cayton RM, Shenoi PM, Skinner C "Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality." Thorax 38 (1983): 813-21

17. Shim C, Williams MH, Jr "Cough and wheezing from beclomethasone aerosol." Chest 91 (1987): 207-9

18. Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993): 680-1

19. Mollura JL, Bernstein R, Fine SR, Vevaina J "Pulmonary eosinophilia in a patient receiving beclomethasone dipropionate aerosol." Ann Allergy 42 (1979): 326-9

20. Klotz LR, Klotz SD, Moeller RK "The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction." Ann Allergy 39 (1977): 133-6

21. Grebe SKG, Feek CM, Durham JA, Kljakovic M, Cooke RR "Inhaled beclomethasone dipropionate suppresses the hypothalamo-pituitary-adrenal axis in a dose dependent manner." Clin Endocrinol (Oxf) 47 (1997): 297-304

22. Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996): 5-16

23. Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975): 29-42

24. Brown PH, Greening AP, Crompton GK "Hypothalamo-pituitary-adrenal axis suppression in asthmatic adults taking high dose beclomethasone dipropionate." Br J Clin Pract 46 (1992): 102-4

25. Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999): 1278-84

26. Sorkin S, Warren D "Probable adrenal suppression from intranasal beclomethasone." J Fam Pract 22 (1986): 449-50

27. Harris DM, Martin LE, Harrison C, Jack D "The effect of oral and inhaled beclomethasone dipropionate on adrenal function." Clin Allergy 3 (1973): 243-8

28. Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992): 327-30

29. Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993): 223-8

30. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992): 414-7

31. Goldstein MF, Fallon JJ, Harning R "Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease." Chest 116 (1999): 1733-49

32. Matsumoto H, Ishihara K, Hasegawa T, Umeda Bi B, Niimi A, Hino M "Effects of Inhaled Corticosteroid and Short Courses of Oral Corticosteroids on Bone Mineral Density in Asthmatic Patients : A 4-Year Longitudinal Study." Chest 120 (2001): 1468-1473

33. Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997): 853-60

34. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995): 571-9

35. Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997): 8-14

36. Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997): 722-7

37. Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993): 1822

38. Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989): 432-3

39. Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990): 489-90

40. Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989): 918

41. Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980): 117-8

42. Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993): 1306-7

43. Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993): 148-50

44. Roy A, Leblanc C, Paquette L, Ghezzo H, Cote J, Cartier A, Malo JL "Skin bruising in asthmatic subjects treated with high doses of inhaled steroids: frequency and association with adrenal function." Eur Respir J 9 (1996): 226-31

45. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY "Purpura and dermal thinning associated with high dose inhaled corticosteroids." Br Med J 300 (1990): 1548-51

46. Mak VH, Melchor R, Spiro SG "Easy bruising as a side-effect of inhaled corticosteroids." Eur Respir J 5 (1992): 1068-74

47. Phelan MC "Beclomethasone mania." Br J Psychiatry 155 (1989): 871-2

48. Goldstein ET, Preskorn SH "Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder." Am J Psychiatry 146 (1989): 1076-7

49. Prenner BM, Chervinsky P, Hampel FC, Howland WC, Lawrence M, Meltzer EO, Munk ZM, Ratner PH, Seltzer JM, Settipane GA, Lor "Double-strength beclomethasone dipropionate (84 mu g/spray) aqueous nasal spray in the treatment of seasonal allergic rhinitis." J Allergy Clin Immunol 98 (1996): 302-8

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.